Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
2013 ◽
Vol 31
(8)
◽
pp. 1846
2004 ◽
Vol 22
(5)
◽
pp. 433
2004 ◽
Vol 22
(5)
◽
pp. 433-433
2017 ◽
Keyword(s):
2012 ◽
Vol 30
(5_suppl)
◽
pp. 157-157
2007 ◽
2007 ◽